Join DS2 at the DIA Canada Annual Meeting 2026
DS2 will be at the Hilton Lac-Leamy in Gatineau on October 26 and 27, across the regulatory, clinical and pharmacovigilance tracks and meeting customers and partners around the sessions. Put a time in with us.
Let's Connect in Gatineau
This meeting puts Health Canada in the room. Three Director Generals are on the programme, covering pharmaceutical drugs, biologics and radiopharmaceuticals, and policy and international affairs, alongside regulatory, clinical operations and pharmacovigilance leaders from AstraZeneca Canada, Bayer, AbbVie, Teva Canada Innovation, Bristol Myers Squibb, Certara and BIOTECanada. Canadian studies carry their own logistics and cross-border questions, and we provide industry-leading solutions across the entire connected sample supply chain. Kits built and shipped to Canadian sites and participants, courier and cold chain across provinces and over the border, chain of custody that satisfies both sides of it, biostorage, and integration back into your systems. We're looking forward to talking through what your Canadian footprint needs.
We often find during these events that the diary fills up quickly. Use the form and we'll block a time for you to meet our team while availability lasts.
Why Attend the DIA Canada Annual Meeting?
DIA describes the meeting as providing "an in-depth exploration of the current pharmaceutical, medical device, and diagnostic landscapes in Canada, emphasizing Canada's pivotal role in global healthcare product development," with the chance to engage leaders and experts from academia, regulatory bodies and industry.
Three tracks, bookended by plenaries: Three tracks run concurrently: Regulatory, Clinical, and Safety and Pharmacovigilance, with plenary sessions opening the meeting and a Health Canada Town Hall closing it.
What the programme covers: The published coverage includes Health Canada's regulatory modernization initiatives, responsible AI across regulatory affairs, clinical development and pharmacovigilance, emerging Canadian and international expectations including ICH E6(R3), E8(R1) and M15, digital technologies and real-world evidence in decision-making, inspection readiness and vendor oversight, and regulatory reliance and harmonization to accelerate patient access.
A 75-speaker faculty: DIA publishes 75 named speakers for the meeting, which is a substantial roster for a two-day national programme.
Why Meet with DS2?
Running a study in Canada adds questions that do not come up elsewhere. Provincial distribution, cross-border movement of specimens, bilingual materials and documentation that has to satisfy Health Canada as well as the agency in your home market. DS2 builds and runs that layer, with the chain of custody and compliance documentation to match. What we do:
- Diagnostic and specimen collection kit design, assembly and fulfillment
- Kit-to-patient and direct-to-patient distribution
- Medical courier services, including STAT and next-flight-out specimen transport
- Cold chain and temperature-controlled logistics, with the documentation to prove the range held
- Biostorage and biorepository services
- Mobile phlebotomy and specimen collection
- LIS, LIMS and EMR integration, including HL7 and FHIR
- Chain of custody and compliance documentation
Kit build and fulfillment into Canadian sites and homes, courier and cold chain across provinces and borders, biostorage, and the integration that brings results back into your systems. We're looking forward to talking it through in Gatineau.
Speaking Faculty
A selection from the speakers published for 2026.
Kelly Robinson
Health Canada
Director General, Pharmaceutical Drugs Directorate
Ed Morgan
HPFB, Health Canada
Director General, Policy, Planning and International Affairs Directorate
Sonia Corrent
Health Canada
Director General, Biologic and Radiopharmaceutical Drugs Directorate
Seema Verma-Pharasi
Health Canada
Executive Director, Regulatory Enablement Services
Jeffrey Skene
Health Canada
Director, Bureau of Cardiology, Allergy and Neurological Science
Sophie Radicke
MHRA, United Kingdom
Head of GPvP and Senior Pharmacovigilance Inspector
Saunya Dover
Canada's Drug Agency
Director, Science and Methods
Tharany Ganesh
AstraZeneca Canada
Head, Regulatory Affairs
Ron Boch
BIOTECanada
Vice President, Biotechnology and Industry Affairs
Anna Bussel
ClaroPV Services
Vice President, Pharmacovigilance and Medical Information
Vandana Oza
Bayer Canada
Head of Medical Governance, Operations and Patient Access
Sandra Krogulski
Bristol Myers Squibb
Senior Director, Regulatory Digital Strategy and External Engagement
The full list of 75 speakers is on the official speakers page.
The Agenda, Day by Day
Times below are as published by DIA. Three tracks run in parallel between the plenaries. The full session list, including every speaker across all three tracks, is on the official agenda page.
Day One · Monday, October 26, 2026
Networking breakfast, with registration open from 07:30
Welcome and opening remarks
Session 1 plenary: Enhancing Regulatory Decisions Using the Digital Advantage, AI-Driven Insights for Seamless Information Sharing and Earlier Access
Case study hosted by Clinevotech
Session 2, across three tracks
Track A: Canada's strategic vision for supply chain security and global harmonization. Track B: what's new in clinical trial regulation. Track C: transforming PV workflows with AI and automation
Luncheon, exhibits and networking break
Session 3, across three tracks
Track A: how Health Canada is streamlining regulatory work. Track B: patient-centric decentralized trials and digital governance. Track C: building and governing high-performing PV partnerships
Case study hosted by ClaroPV: Building Effective Cross-Functional Partnerships to Strengthen Pharmacovigilance Compliance
Session 4, across three tracks
Track A: model-informed drug development and precision medicine. Track B: community-led engagement and researchers in trial development. Track C: applying Health Canada's 2026 pharmacovigilance guidance
Session 5, across three tracks
Track A: real-world data integration and patient-centered market access. Track B: advancing pediatric clinical trials. Track C: pharmacovigilance inspection readiness from Health Canada GVP insights to global compliance
Networking reception
Day Two · Tuesday, October 27, 2026
Networking breakfast, with registration open from 07:30
Session 6, across three tracks
Track A: AI capabilities in regulatory content and submissions. Track B: advancing clinical development with AI. Track C: adapting global promotional materials for the Canadian market
Refreshments, exhibits and networking break
Session 7, across three tracks
Track A: risk-based approaches to package inserts, XML product monograph authoring and CMC trends. Track B: translating ICH E6(R3) into action. Track C: managing safety risks in self-care products
Luncheon, exhibits and networking break
Session 8, across three tracks
Track A: enabling harmonization and reliance for faster access. Track B: operationalizing ICH E8(R1) and E6(R3). Track C: applying real-world evidence in Canada
Refreshments, exhibits and networking break
Session 9 plenary: Health Canada Town Hall
Closing remarks
Useful DIA Canada Annual Meeting Resources
The official event page.
AgendaThe full two-day programme across all three tracks.
SpeakersThe published faculty.
RegisterRates, windows and group terms.
Hotel InformationThe Hilton Lac-Leamy block.
ExhibitsExhibit and marketing opportunities.
Terms and ConditionsCancellation and transfer policy.
DIA Canada Annual Meeting 2026 FAQ
General
Fees & registration
Venue & travel
See You in Gatineau
Gatineau, October 26 and 27. Tell us where your Canadian sites and participants are and we'll put time aside to work through the logistics.